STEMEZ hNeural Progenitors and Cell Migration

I first featured Dr. Steve Stice in August 2008. I have since done follow up posts based on the excellent studies they have been conducting using our  STEMEZ (TM) Human Neural Progenitor & Neuron Discovery Kits.

I would like to highlight a poster based on research Steve and his Team conducted with Platypus Technologies.

Allan C. Powe, Jr., Kathryn L. Hodges, Jamie M. Chilton, Scott Gehler, Renee L. Herber, Keren I. Hulkower, Steven L. Stice. Identification of stimulators and inhibitors of cell migration in human embryonic stem cell derived neural progenitors using a novel, high throughput amenable assay platform.

Investigates the migratory behavior of an adherent monolayer neural progenitor cell line derived from human embryonic stem cells (hNP1 ™; ArunA Biomedical)using a novel 96‐well based cell migration assay platform (Oris™ Cell Migration Assay; Platypus Technologies) amenable for high throughput screening. The assay platform uses stoppers to create central exclusion zones within the wells; cells are plated outside the zone and migrate inward once the stopper is removed.

Data suggest this is a tool for understanding proper nervous system development, development of therapies for cell migration defects, and identifying novel environmental neurotoxicants.

Conclusions:
—The hNP1™ Oris™ Cell Migration Assay can quantitatively detect both stimulators and inhibitors of cell migration.
—Method development to date indicates that the assay has the potential for adaptation as a homogenous HTS‐suitable cell‐based assay.
—Preliminary results suggest that bFGF alone has a potent chemokinetic effect while LIF and GDNF act synergistically to drive migratory behavior during dopaminergic differentiation.

Featuring Dr. Richard Rogers

Obesity Energy, Thermogenesis and Appetite

Dr. Richard Rogers

Dr. Richard Rogers

 
Obesity and its evil twin, diabetes, are rapidly becoming our #1 health epidemic. Today 10% of all medical costs in the U.S. are dueto an overweight population, and this percentage is growing rapidly. Today, the breakdown is about $1500 per year in medical costs for obese versus normal weight individuals. This translates into more than $145 billion spent annually.
Given the size of the epidemic, a growing focus for my company is providing reagents to researchers who study bioprocesses involved in energy metabolism. This includes researchers studying what happens to energy expenditure when the “fuel tank” is full and also empty. Both states could give clues as to why we overeat.

In my routine follow up with researchers using our reagents, I started to get an appreciation on how these complex energy pathways are being unraveled and better understood. That appreciation forms the roots of this “News Behind the Neuroscience News” story. It is a story that has the hormones Leptin and TRH playing a starring role supported by hindbrain neuro/glial-circuitry and brown adipose tissue (BAT).

The Rogers Lab

I became aware of the Richard Rogers Lab in my follow up with Montina Van Meter checking on our  LepRb/OBRb antibody. She shared that it was giving them results better than most others they has used. She then gave me an overview of her research involved with  the control of feeding behavior and energy utilization including thermogenesis (“heat generation”) catalyzed in BAT.  Cool…this was a lab we wanted to make sure we served and served well.

Tina not only kept me informed on how our reagents were working, but also generously alerted to me publications referencing use of our reagents:
·        Maria J. Barnes, Richard C. Rogers, Montina J. Van Meter and Gerlinda E. Hermann. Co-localization of TRHR1 and LepRb
receptors on neurons in the hindbrain of the rat.
 doi:10.1016/j.brainres.2010.07.094…Included are excellent images of stained LepRb (OB-Rb)-(Dilution 1:500) and  GAD1-Dilution (2ug/ml) expressing neurons localized in loose clusters of cells in the DMN, NST, and the VLM…
·        Hung Hsuchou, Yi He, Abba J. Kastin, Hong Tu, Emily N. Markadakis, Richard C. Rogers, Paul B. Fossier, and Weihong Pan. Obesity induces functional astrocytic leptin receptors in hypothalamus. Brain, Mar 2009; doi:10.1093/brain/awp029…unique sequence of ObRb at its cytoplasmic tail (CH14104, Neuromics, Edina, MN, USA). This antibody was raised
against rat ObRb…

I found this research to be unique and intriguing. This led me to an interview with Dr. Rogers. Here is his backstory.

Beginnings

Dr. Rogers credits serendipity as a driving force in his interest in Neuroscience. It started with a bike ride and chance introduction with a ham radio operator when he was a youngster. This catalyzed his interest in electronics and circuitry.

This interest morphed to a passion for Neuroscience (circuits and signaling). He entered the first college program devoted to Neuroscience studies at UCLA.  He received his Ph. D. in 1979. His post-doc focused on digestive regulation. Here, he  investigated the neural circuitry involved in the normal control of gastric function.

Evolutions

In collaboration with his wife Dr. Gerlinda Hermann, his work evolved to solving the mystery of why we don’t eat (abnormal gastric function). What causes gastro-intestinal shutdown?  The breakthrough was their ability to show cross-talk between the immune system and nervous system. This research is a foundation for the discovery of therapies for sufferers of appetite shut down cause by cancer therapies and certain immune related pathologies.

The main culprit is TNF-α. The blood level of this peptide is elevated as a consequence of immune activation caused by infection, cancer, radiation exposure and chronic autoimmune disease. The breakthrough was showing that  TNF-α receptors are on neurons in the brainstem that control gastric functions, including emesis.  Neurons in the nucleus of the solitary tract (NST) respond to TNF-α greatly increasing the sensitivity of gastric vagal control circuitry.  This causes emptying of the gut to dramatically slow,l leading to nausea, vomiting and cessation of appetite.

Currently, they are delving into the complexities of  TNF-α signaling processes. This includes the role of astrocytes and glia.

See: Gerlinda E Hermann and Richard C Rogers.  TNF activates astrocytes and catecholaminergic neurons in the solitary nucleus: implications for autonomic control. doi: 10.1016/j.brainres.2009.03.059.

 Energy,Obesity and Thermogenesis-Active Astrocytes

Recently, the lab took another road less traveled. Dr. Gerlinda Hermann discovered interesting aspects of leptin and thyrotropin releasing hormone (TRH) signaling.  This research looks at signaling in thermogenesis and feeding behavior. A most interesting aspect includes conclusions concerning the role of astrocytes.  Their colleague Dr. Weihong Pan  showed that adult obese mice, (2 months after being placed on a high-fat diet) showed a striking increase of leptin receptor (+) astrocytes, most prominent in the dorsomedial hypothalamus and arcuate nucleus. Agouti viable yellow mice with their adult-onset obesity showed similar changes, but the increase of leptin receptor (+) astrocytes was barely seen in ob/ob or db/db mice with their early-onset obesity and defective leptin systems. The results indicate that metabolic changes in obese mice can rapidly alter leptin receptor expression and astrocytic activity, and that leptin receptor is responsible for leptin-induced calcium signalling in astrocytes. This novel and clinically relevant finding opens new avenues in astrocyte biology (doi: 10.1093/brain/awp029).

Non-shivering thermogenesis usually occurs in BAT. It uncouples the ATP energy producing process by generating heat rather than driving the conversion of ADP to ATP. This creates an ingenious way to untangle complex processes related to Leptin signaling. What happens when there is sufficient energy for the thermogenic process? Conversely, what happens when there is insufficient energy?

 Leptin and TRH act synergistically in the hindbrain to drive thermogenesis. However, in a starving condition there is a subsequent drop in Leptin and thermogenesis. Behind these simple facts are complex processes that occur in the hindbrain. The team is providing important insights including location of events and relevant signaling molecules. (doi:10.1016/j.brainres.2010.07.094).

The Future-Caged Compounds and Live Cell Signaling

Caged compounds are bioactive molecules attached to photolabile groups, that release the active component on contact with photons of the right energy level – the process of photolysis. Photolysis is now widely applied in biology to induce neurotransmitter and otherm ligand-receptor interactions in conditions that are otherwise subject to poor diffusional access and receptor desensitization, as well as for labile ligands.

This novel technology affords Dr. Rogers and his team the capability do live cell imaging of calcium signaling. From these they will help us gain a deeper understanding of what is happing and where. Specifically, we will more exactly learn the role that astrocytes and glia play in controlling the role of   Leptin and related signaling molecules in controlling energy, metabolism and feeding behavior. This could lead to important target for future therapies.

On Deck-Dr. Richard Rogers

I am exciting to be profiling Dr. Richard Rogers in my upcoming Neuroscience Backstory feature. This is an important feature because it focuses on the timely topic of modulation of the brain-gut axis by cytokines, hormones and CNS pathways involved in the control of feeding behavior and energy utilization. Given the acceleration in the growth of obesity in the US and related pathologies, his research is becoming increasingly important.  We will also be featuring related research on what drives lack of appetite in cancer patients. This is a key intersection as the signaling pathways involved in insatiable and cessation of appetite are related.

I also wanted to share a recent article on yet another intersection which focuses on thermogensis which occures in brown adipose tissue (BAT): Maria J. Barnes, Richard C. Rogers, Montina J. Van Meter and Gerlinda E. Hermann. Co-localization of TRHR1 and LepRb receptors on neurons in the hindbrain of the rat. doi:10.1016/j.brainres.2010.07.094.

LepOBRB-TRHR3

Example images: Distribution of LepRb+ fibers in hindbrain. LepRb-ir (red) fibers and varicosities are seen among TRHR1-ir (green) cells and fibers. These red and green fibers are adjacent and co-mingle but do not show co-localization of receptors. This pattern is seen in (A) fascicles of the solitary tract (ST); (B) raphe pallidus (RP), and (C) raphe obscurrus (RO). (D) Border between the medial solitary nucleus (NST) and the area postrema (AP; white dashed line) showing an abundance of LepRb-ir (red) fibers and
 neurons (white arrows for selected neurons) in the NST but not the AP. (E) LepRb-ir staining is suppressed by pretreatment of tissue with LepRb epitope blocking peptide. (F) TRHR1-ir staining is suppressed by treatment with excess TRHR1. Scale bar A–D=100 microns; E, F=300 microns. cc=central canal. Note: this pus references use of our LepRb (OB-Rb) and GAD1 antibodies.

Intra-i-Fect Tissue Specific siRNA Kits

I have published content here on our collaborator’s success using i-Fect to delivery siRNA in vivo and in-vitro. These kits have been used for gene expression analysis studies of DOR, hTERT, The β3 subunit of the Na+,K+-ATPase, rSNSR1, NTS1. NAV1.8, Survivin,  Flaviviruses and more.

I am excited about another iteration of capablilities with our new:
Intra-i-Fect Tissue Specific siRNA Kits.

These kits are designed to deliver siRNA in vivo via intravenous injections with high efficiency to specific tissue in rats and mice. The protocol involves these simple steps: prep, mix, dry, hydrate and inject.

They are developed using a proprietary platform that uses nano-particles as the delivery vehicle. This platform enables:

  • Effective delivery (60%+ knockdown) with no toxicity.
  • Scalable to high throughput siRNA based gene screening.
  • Consistent and reproducible results

Dr. Steve Hall knows Stem Cells

 
Developing New Methods, Applications and Reagents for Regenerative Medicine and Stem Cell Research.
 Getting Started with Alphagenix                    

Steve is an advisor, collaborator and friend. He has the innate ability to bring his his scientific expertise and entrepreneural insticts together in a way that anticipates emerging needs of the research community we both serve. He is an expert in immunology, neuroscience, virology and regenerative medicine (stem cells).  Most notably, he is the sole inventor on the patent that formed the basis for using the Nodaviruses as vaccine and gene therapy vectors U.S. Patent 6,171,591. These vaccines are in various stages of preclinical development as are protoype therapeutic vaccines for neurodegenerative diseases. 

Our two companies first worked together to identify and manufacture several important stem cell markers. We tested potency on our STEMEZ hNP1TM Human Neural Progenitors. They proved to be effective. This confirmed Steve’s ability to identify, design and make these markers. The demand for them continues to grow.

These successes were a prelude of good things to come.

Current Focus

Steve is currently  developing novel products and technologies for basic and clinical research with a particular emphasis on stem cell markers, biomaterials and regenerative medicine. The biomaterials product focus involves the design and application of 3-dimensional biomaterials comprised of extracellular matrix components and peptide nanofibers that have cell culture and tissue engineering applications. In addition, the company conducts regenerative medicine research that involves basic science and translational preclinical research using stem cell regulatory network discoveries and novel preclinical studies utilizing animal models with a focus on neurological disease and diabetes.

He is a contributor to: Stem Cell Therapy for Neurological Diseases Stem cell therapy for the treatment of acute and chronic neurological diseases

Dr. Steve Hall

2001-Present-President-Alphagenix

2006-2007-CSO-Neuromics

2000-2001-President-AmProx, Inc

1996-2004-President and CSO-Pentamer Pharmaceuticals

1996-1997-Sr. Research Fellow-Medical Biology Institute.

1995-1997-Research Associate-Scripps Research Institute

1995 PhD Purdue University

Musashi-1 Antibody

Musashi-1 Antibody

Image: Musashi (green) staining of neural rosettes(human). Nuclei are counterstained blue (DAPI). Image courtesy of Dr. Steve Stice and Dr. Patricia Wilson, University of Georgia.

 

 

Harting, Matthew T., Cox, Charles S. and Hall, Stephen G.  Adult Stem Cell Therapy for Neurological Disease: Preclinical evidence for cellular therapy as a treatment for neurological disease. In Vemore and Vinoglo (eds): Regulatory Networks in Stem Cells. Humana Press, pp 561-573, (2009). More information.

Specific Projects

  1. Steve has 3 major projects underway:
    In collaboration with Dr.  Charles Cox , Distinguished Professor, UT Medical School @ Houston, Steve has been using stem cells to treat  Traumtaic Brain Injury (TBI) in Rat. Neural stem cells transplanted into the site of injury. In this model, treated rats showed injury significantly improved motor skills with a moderate recovery in cognitive ability. This research forms the base for eventually repairing damage in humans suffering TBI. Methods and reagents developed also could be useful for basic research and drug discovery.
  2. Steve is working with Burnham Institute to develop methods for using  Human Mesenchymal Stem Cells to regenerate beta cells. This research holds promise for type 1 diabetics.
  3. Steve developing biomaterials including extracellular matrix proteins in novel cell culture systems and synthetic peptide nanofibers for these purposes.  It is investigating stem cells and genetically engineered cells and their interaction with these biomaterials, which has the ability to increase the efficacy of cell therapy. This is highlighted by a human laminin sytem that shows promise in restoring function in Muscular Dystophry.

The last project is promising enough that it could lead to funding for phase 1 testing.

I will continue to keep you posted on progress. I am excited about the new regeants and method that evolve from Steve’s Research. As these prove to work in unique and novel ways, the will become available to Neuromics.

Dr. Steve Stice to Present the Power of StemEZ Neural Cells

STEMEZ hN2 Primary Human Neurons

STEMEZ hN2 Primary Human Neurons

I have profiled Steve Stice’s research here. The focus has been the excellent research results he and his team at ArunA Biomedical have generated with STEMEZ(TM) hN2 Human Neurons and hNP1 Human Neural Progenitors.

The story continues. He will be presenting the latest at the 9th Annual World Pharmaceutical Congress in Philadelphia, June 14. Topics include: using these neural cell lines to study neurotoxicity in cell-based assays and disease modeling.  Recent work conducted in outside laboratories demonstrates that these lines are more sensitive to environmental toxicants than traditional cellular models.

Sample high throughput assay applications:

  • Cell morphology and neurite outgrowth
  • Cell signaling and transcription factor expression
  • Receptor and ion channel function
  • Cytotoxicity
  • Apoptosis, genotoxicity and DNA damage

These capabilities has been confirmed by our customers. I look for the use of the STEMEZ cell lines to continue to grow as researchers discover their value in Drug Discovery and Basic Neuroscience capabilities.

Coming Soon-Dr. Steve Hall

Dr. Steve Hall

Dr. Steve Hall

Dr Steve Hall has been a friend, collaborator and mentor since I purchased Neuromics. This includes being a Neuromics’ Premier supplier of Stem Cells and Related Markers, Media and Methods. Steve is currently President at AlphaGenix, Inc.

His expertise includes developing novel products and technologies for basic and clinical research with a particular emphasis on stem cell markers, biomaterials and regenerative medicine. The biomaterials product focus involves the design and application of 3-dimensional biomaterials comprised of extracellular matrix components and peptide nanofibers that have cell culture and tissue engineering applications. In addition, the company conducts regenerative medicine research that involves basic science and translational preclinical research using stem cell regulatory network discoveries and novel preclinical studies utilizing animal models with a focus on neurological disease.

He is a contributor to: Stem Cell Therapy for Neurological Diseases Stem cell therapy for the treatment of acute and chronic neurological diseases

Harting, Matthew T., Cox, Charles S. and Hall, Stephen G.  Adult Stem Cell Therapy for Neurological Disease: Preclinical evidence for cellular therapy as a treatment for neurological disease. In Vemore and Vinoglo (eds): Regulatory Networks in Stem Cells. Humana Press, pp 561-573, (2009). More information.

Stay tuned for Steve’s backstory in June!

Studying Apoptosis In Tumors

I have featured Gary Johnson here.

I value my partnership with his compant, ICT. They provide our customers with potent and research proven Apoptosis Kits and Methods. Here we feature publications referencing our MitoPT™ Kits. These Kits easily assess changes in mitochondrial membrane potential. Changes in mitochondrial membrane potential can correlate with cytochrome c release and the initiation of apoptosis.
A431 cells, treated with predetermined IC50
concentration of novel anticancer agents, fluoresce green and orange-red with MitoPT JC-1. Data courtesy of Zayas/ Carro, Universidad Metropolitana.
Anticancer Effects of Alpinia pricei Hayata Roots.
CL Hsu, YS Yu, GC Yen. J. Agric. Food Chem., Jan 2010, 58 (4), pp 2201–2208.

Anticancer Effects of Flavonoid Derivatives Isolated from Millettia
reticulata Benth in SK-Hep-1 Human Hepatocellular Carcinoma Cells.

SC Fang, CL Hsu, HT Lin, GC Yen. J. Agric. Food Chem., Jan 2010, 58
(2), pp 814–820.

Mechanisms of Apoptotic Effects Induced by Resveratrol,
Dibenzoylmethane, and Their Analogues on Human Lung Carcinoma Cells.

CJ Weng, YT Yang, CT Ho, GC Yen. J. Agric. Food Chem., Jun 2009; 57
(12), pp 5235–5243.

TCE and Parkinson’s

This post introduces a new twist to “News Behind the Neuroscience News”. This report was graciously submitted by Ms Pamela Brown of associatesdegree.com. I welcome her initiative in submitting this. On a side note, when I did factory work in the 1970s, trichloroethylene was a universal solvent used to clean parts. Wow. We will add more to the story as Researchers continue their studies. Thank you Pamela!

Of Chemicals and Parkinson’s Disease

Two recent studies have linked the chemical TCE, an industrial solvent, to the increased risk of Parkinson’s disease.  The first study, led by the University of Kentucky’s Don M. Gash and John T. Slevin, established a clear link between trichloroethylene and parkinsonism , which is a group of nervous disorders closely associated with Parkinson’s.

 The study investigated a group of people who had been occupationally exposed to TCE for over twenty-five years. Gash and Slevin found that of the 134 participants interviewed, 14–the group that worked closest to the TCE vat cleaning industrial parts–showed strong signs of Parkinsonism. 13 other patients who had worked further from the TCE source also showed signs of the disorder, although in milder form. The University of Kentucky study extended its investigation by exposing rats to TCE. The rats’ mitochondrial function was substantially inhibited and their dopamine-producing cells were severely damaged.

 A more recent study , revealed in January, established an even stronger link between TCE and Parkinson’s. Dr. Samuel Goldman, a researcher at the Parkinson’s Institute in Sunnyvale, California, examined 99 sets of twins in which one twin had Parkinson’s and the other didn’t. Goldman and his team gathered job histories from the group of twins and had an industrial hygienist evaluate the twins’ level of chemical exposure. The study found that those exposed to TCE had an almost six-fold increased risk of developing Parkinson’s. Occupations that often involve exposure to TCE include machinists, laundry cleaners, and electricians.

Even though the most recent findings are substantial, the idea that chemicals may be associated with increased risk of developing Parkinson’s is not very new. Earlier studies have suggested that certain pesticides and herbicides may increase risk as well.

Not all chemicals are bad news for Parkinson’s patients. A brain chemical, identified only about twenty years ago and named after the video game character, Sonic Hedgehog , has been shown to decrease the risk of developing Parkinson’s, meaning that increasing the chemical may be a viable treatment for the disease. Another study has suggested that urate, a naturally occurring chemical in the blood, may slow the progression of Parkinson’s, although the chemical has been proven to cause gout.

By-line:

This guest post is contributed by Pamelia Brown, who writes on the topics of associate degree .  She welcomes your comments at her email Id: pamelia.brown@gmail.com

Opioid-Induced Hyperalgesia and CaMKII alpha

Many of my backstories have featured Pain Researchers.  In several, I have featured use of our our i-Fect ™ Transfection Kit for enhancing the delivery of siRNA in vitro and in vivo to study the expression of genes invovled in Neuropathic and Nociceptive Pain.

I am excited to present a recent publication that includes use of this kit to study Opioid-Induced Hyperalgesia. In this study Dr. Zaijie Jim Wang and his team at University of Illiniois Chicago down regulate CaMKII alpa expression. Their data implicates, for the first time, an essential role of CaMKII alpha as a cellular mechanism leading to and maintaining opioid-induced hyperalgesia.

Yan Chen, Cheng Yang, and Zaijie Jim Wang. Ca2+/Calmodulin-Dependent Protein Kinase II Is Required for the Initiation and Maintenance of Opioid-Induced Hyperalgesia. The Journal of Neuroscience, January 6, 2010, 30(1):38-46; doi:10.1523/JNEUROSCI.4346-09.2010.

…KN93 and KN92 were administered intrathecally by percutaneous puncture through the L5-L6 intervertebral space, as described previously (Hylden and Wilcox, 1980; Chen et al., 2009). A lateral tail flick was considered as success of the intrathecal injection. To inhibit CaMKII, CaMKII was targeted by small interfering RNA (siRNA). Four days after morphine pellet implantation, mice were treated with CaMKII siRNA (5′-CACCACCAUUGAGGACGAAdTdT-3′, 3′-dTdTGUGGUGGUAACUCCUGCUU-5′) (Zayzafoon et al., 2005) or Stealth RNAi negative control (Invitrogen) (2 µg, i.t., twice per day for 3 consecutive days). These oligos were mixed with the transfection reagent i-Fect (Neuromics), in a ratio of 1:5 (w/v) (Luo et al., 2005). Mechanical and thermal sensitivity tests were performed daily…